{"title": "Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China, January and February 2020", "doi": "10.1101/2020.03.04.20031104", "citation_id": "2020.03.04.20031104v1", "date": "2020-03-06", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.04.20031104", "abstract": "<p>The coronavirus disease 2019 (COVID-19) epidemic that originated in Wuhan, China has spread to more than 60 countries. We estimated the age-specific case fatality ratio (CFR) by fitting a transmission model to data from China, accounting for underreporting of cases and the time delay to death. Overall CFR among all infections was 1.6% (1.4-1.8%) and increased considerably for the elderly, highlighting the expected burden for populations with further expansion of the COVID-19 epidemic around the globe.</p>", "twitter_description": "The coronavirus disease 2019 (COVID-19) epidemic that originated in Wuhan, China has spread to more than 60 countries. We estimated the age-specific case fatality ratio (CFR) by fitting a transmission model to data from China, accounting for underreporting of cases and the time delay to death. Overall CFR among all infections was 1.6% (1.4-1.8%) and increased considerably for the elderly, highlighting the expected burden for populations with further expansion of the COVID-19 epidemic around the globe.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nJR is funded by the Swiss National Science Foundation (grant 174281). MC is funded by the Swiss National Science Foundation (grant 176233).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll code and data are available from https://github.com/jriou/covid\\_adjusted\\_cfr", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031104v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031104v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031104v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/06/2020.03.04.20031104.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.04.20031104v1", "access_rights": "restricted", "authors": ["Julien Riou", "Anthony Hauser", "Michel J Counotte", "Christian L Althaus"]}